Suppr超能文献

CD8+ 肿瘤浸润淋巴细胞与高级别浆液性卵巢癌生存时间的剂量-反应关系。

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

机构信息

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA

出版信息

JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.

Abstract

IMPORTANCE

Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors.

OBJECTIVE

To define the prognostic role of CD8+ TILs in epithelial ovarian cancer.

DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years.

EXPOSURES

Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines.

MAIN OUTCOMES AND MEASURES

Overall survival time.

RESULTS

The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form.

CONCLUSIONS AND RELEVANCE

This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.

摘要

重要性

细胞毒性 CD8+肿瘤浸润淋巴细胞(TILs)参与上皮性卵巢癌的免疫控制;然而,关于 CD8+TILs 的组织学类型和与其他临床因素的关系的预后模式知之甚少。

目的

确定 CD8+TILs 在上皮性卵巢癌中的预后作用。

设计、地点和参与者:这是卵巢肿瘤组织分析联盟的一项多中心观察性、前瞻性生存队列研究。超过 5500 名患者,包括 3196 名高级别浆液性卵巢癌(HGSOC)患者,前瞻性随访超过 24650 人年。

暴露

在免疫组织化学分析后,在肿瘤岛的上皮成分内鉴定出 CD8+TILs。根据每个高倍视野估计的 CD8+TIL 数量将患者分为:阴性(无)、低(1-2)、中(3-19)和高(≥20)。还以定量、非分类的方式评估了部分患者的 CD8+TIL,并使用惩罚 B 样条评估与生存的关联的函数形式。

主要结局和测量

总生存时间。

结果

最终样本包括 5577 名女性;诊断时的平均年龄为 58.4 岁(中位数,58.2 岁)。在 5 种主要侵袭性组织学类型中,HGSOC 显示出最明显的浸润。HGSOC 中的 CD8+TILs 与更长的总生存时间显著相关;无 CD8+TILs 的患者中位生存时间为 2.8 年,低、中、高 CD8+TILs 水平的患者分别为 3.0 年、3.8 年和 5.1 年(趋势 P 值=4.2×10−16)。在子宫内膜样癌和黏液性癌患者中也观察到生存获益,但在其他组织学类型的患者中未观察到。在 HGSOC 中,无论肿瘤细胞减灭术后残留疾病的程度、已知的标准治疗和种系 BRCA1 致病性突变如何,CD8+TILs 都是有利的,但对 BRCA2 突变携带者没有预后意义。对未分类的 CD8+TIL 计数的评估显示出近对数线性的功能形式。

结论和相关性

本研究证明了免疫浸润的组织学特异性,并为 CD8+TILs 与 HGSOC 生存之间的剂量反应关系提供了明确证据。浸润的程度是预后的,而不仅仅是存在或不存在,这表明理解驱动浸润的因素将是解开这种癌症结局异质性的关键。

相似文献

6
CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.CD137+ 肿瘤浸润淋巴细胞预测卵巢癌生存。
Gynecol Oncol. 2024 May;184:74-82. doi: 10.1016/j.ygyno.2024.01.029. Epub 2024 Jan 29.

引用本文的文献

本文引用的文献

3
Ovarian cancer epidemiology in the era of collaborative team science.协作团队科学时代的卵巢癌流行病学
Cancer Causes Control. 2017 May;28(5):487-495. doi: 10.1007/s10552-017-0862-6. Epub 2017 Mar 10.
4
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
10
An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.一种用于卵巢癌分型的免疫组织化学算法
Int J Gynecol Pathol. 2016 Sep;35(5):430-41. doi: 10.1097/PGP.0000000000000274.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验